Acknowledgement
We appreciate all of the department's and hospital's medical and non-medical staff's hard work and support on this project.
References
- Baniasadi S and F Fahimi. Adverse drug reactions in a pulmonary teaching hospital: Incidence, pattern, seriousness, and preventability, Current drug safety, 2011;6(4): 230-236. https://doi.org/10.2174/157488611798280942
- Bhananker SM, et al. The risk of anaphylactic reactions to rocuronium in the United States is comparable to that of vecuronium: an analysis of food and drug administration reporting of adverse events, Anesthesia & Analgesia, 2005; 101(3): 819-822. https://doi.org/10.1213/01.ANE.0000175213.87556.D8
- Brettner A, et al. Pulmonary complications of drug therapy, Radiology, 1970; 96(1): 31-38. https://doi.org/10.1148/96.1.31
- Fens T, et al. Economic evaluations of chronic obstructive pulmonary disease pharmacotherapy: how well are the real-world issues of medication adherence, comorbidities and adverse drug-reactions addressed?, Expert Opinion on Pharmacotherapy, 2021;1-13.
- Gallelli L, et al. Retrospective analysis of adverse drug reactions to bronchodilators observed in two pulmonary divisions of Catanzaro, Italy, Pharmacologicalresearch, 2003; 47(6): 493-499.
- Galli JA, et al. Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: tolerability and adverse drug reactions, Respirology, 2017;22(6): 1171-1178. https://doi.org/10.1111/resp.13024
- Hanlon P, et al. Examining patterns of multimorbidity, polypharmacy and risk of adverse drug reactions in chronic obstructive pulmonary disease: a cross-sectional UK Biobank study, BMJ open, 2018; 8(1): e018404. https://doi.org/10.1136/bmjopen-2017-018404
- Hartwig SC, et al. Preventability and severity assessment in reporting adverse drug reactions, American journal of hospital pharmacy, 1992;49(9): 2229-2232.
- Hire R, et al. A prospective, observational study of adverse reactions to drug regimen for multi-drug resistant pulmonary tuberculosis in central India, Mediterranean journal of hematology and infectious diseases, 2014; 6(1).
- Johnson DB, et al. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study, Journal for immunotherapy of cancer, 2019; 7(1): 1-9. https://doi.org/10.1186/s40425-018-0484-x
- Maqbool M, et al. Drug safety and Pharmacovigilance: An overview, Journal of Drug Delivery and Therapeutics, 2019; 9(2-s): 543-548.
- Maqbool M, et al. Adverse Drug Reaction Monitoring And Occurrence In Drugs Used In Pulmonary Disorders, Indo American Journal Of Pharmaceutical Sciences, 2018; 5(8): 8060-8065.
- Maqbool M, et al. Adverse Events Of Blood Transfusion And Blood Safety In Clinical Practice, Indo American Journal Of Pharmaceutical Sciences, 2018; 5(8): 8254-8259.
- Naranjo C, et al. Naranjo ADR probability scale, Clin Pharmacol Ther, 1981; 30: 239-245. https://doi.org/10.1038/clpt.1981.154
- Petrova G, et al. Assessment of the expectancy, seriousness and severity of adverse drug reactions reported for chronic obstructive pulmonary disease therapy, SAGE open medicine, 2017;5: 2050312117690404.
- Salem JE, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study, The lancet oncology, 2018; 19(12): 1579-1589. https://doi.org/10.1016/S1470-2045(18)30608-9
- Singh A, et al. Prevalence of adverse drug reaction with first-line drugs among patients treated for pulmonary tuberculosis, Clinical Epidemiology and Global Health, 2015; 3: S80-S90. https://doi.org/10.1016/j.cegh.2015.10.005
- Sossai P, et al. Can a drug-induced pulmonary hypersensitivity reaction be dose-dependent? A case with mesalamine, The Mount Sinai journal of medicine, New York, 2001; 68(6): 389-395.